A Phase 2 interventional study of UCB7665 and Placebo in Myasthenia Gravis, sponsored by UCB Biopharma S.P.R.L.. Completed at 20 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-03.
Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing rozanolixizumab in Myasthenia Gravis — 2 open to participants now, 4 under way, 3 of them phase 3. rozanolixizumab · Myasthenia Gravis.
Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, this one is the 7th largest by enrollment, is the only one that started in 2017, is the only one in phase 2, and was the 1st registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →2 of the 10 studies testing rozanolixizumab in Myasthenia Gravis are open now, in 9 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, China and 6 more countries
Ages 18+
By country, each count listing its studies:
rozanolixizumab: first FDA approval 2023 (RYSTIGGO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 8 · Phase 4 1
First in 2017; this study’s year is marked. 1 started in 2017.
This study's enrollment of 43 is close to the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 67 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under UCB Biopharma S.P.R.L., one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma S.P.R.L. is the lead sponsor of 48 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
18 studies in Myasthenia Gravis by UCB S.A.: 5 open now, 7 under way, 5 of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 11th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 1st registered.
UCB S.A.’s Myasthenia Gravis studies by the year they started, since 2017.
2 of the studies testing rozanolixizumab in Myasthenia Gravis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06540144Phase 3UCB Biopharma SRLAn Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | 2027-10-05 |
| NCT07246564UCB Biopharma SRLPhase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, from their registry updates:
Among UCB S.A.’s 18 in Myasthenia Gravis:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the clinical efficacy of UCB7665 as a chronic-intermittent treatment in subjects with generalized myasthenia gravis (MG) who are classified as moderate to severe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized in dosage regimen 1 will receive 3 doses of UCB7655 (dose 1) in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
Drug: UCB7665
Subjects randomized in dosage regimen 2 will receive 3 doses of placebo in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
Drug: UCB7665 · Other: Placebo
UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)
Also known as: Rozanolixizumab
Placebo will be administered in period 1 of dosage regimen 2.
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score to Visit 9
The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3). The score ranges from 0 to 39, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
Time frame: From Baseline to Visit 9 (up to Day 29)
Change From Baseline in Myasthenia Gravis-Composite Score to Visit 9
The total Myasthenia Gravis (MG)-composite score was obtained by summing the responses to each individual item (10 items; Grade: 0-9 depending on item). The score ranges from 0 to 50, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
Time frame: From Baseline to Visit 9 (up to Day 29)
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MGADL) Score to Visit 9
The total MGDAL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3). The score ranges from 0 to 24, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
Time frame: From Baseline to Visit 9 (up to Day 29)
The study started to enroll patients in May 2017 and concluded in August 2018.
| Milestone | Placebo | UCB7665 (7 mg/kg) | Placebo - UCB7665 (7 mg/kg) | Placebo - UCB7665 (4 mg/kg) | UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) | UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) |
|---|---|---|---|---|---|---|
| Started | 22 | 21 | 0 | 0 | 0 | 0 |
| Completed period 1 | 22 | 21 | 0 | 0 | 0 | 0 |
| Completed period 1 and started period 2 | 22 | 20 | 0 | 0 | 0 | 0 |
| Completed | 22 | 20 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | UCB7665 (7 mg/kg) | Placebo - UCB7665 (7 mg/kg) | Placebo - UCB7665 (4 mg/kg) | UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) | UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 11 | 11 | 10 | 10 |
| Completed | 0 | 0 | 8 | 11 | 10 | 10 |
| Not completed | 0 | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 3 | 0 | 0 | 0 |
| Milestone | Placebo | UCB7665 (7 mg/kg) | Placebo - UCB7665 (7 mg/kg) | Placebo - UCB7665 (4 mg/kg) | UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) | UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) |
|---|---|---|---|---|---|---|
| Started | 22 | 21 | 11 | 11 | 10 | 10 |
| Completed | 22 | 21 | 11 | 11 | 9 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3). The score ranges from 0 to 39, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
| scores on a scale | Placebo (FAS) | UCB7665 (7 mg/kg) (FAS) |
|---|---|---|
| Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score to Visit 9 | -1.2 ± 0.6 | -1.8 ± 0.6 |
The total Myasthenia Gravis (MG)-composite score was obtained by summing the responses to each individual item (10 items; Grade: 0-9 depending on item). The score ranges from 0 to 50, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
| scores on a scale | Placebo (FAS) | UCB7665 (7 mg/kg) (FAS) |
|---|---|---|
| Change From Baseline in Myasthenia Gravis-Composite Score to Visit 9 | -1.2 ± 0.9 | -3.1 ± 0.9 |
The total MGDAL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3). The score ranges from 0 to 24, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
| scores on a scale | Placebo (FAS) | UCB7665 (7 mg/kg) (FAS) |
|---|---|---|
| Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MGADL) Score to Visit 9 | -0.4 ± 0.5 | -1.8 ± 0.5 |
Collected over From the start of Treatment Period at Baseline and up to Observation Period at 8 weeks after the final dose of IMP.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (SS) | 0/22 (0%) | 2/22 (9.1%) | 7/22 (31.8%) |
| UCB7665 (7 mg/kg) (SS) | 0/21 (0%) | 0/21 (0%) | 13/21 (61.9%) |
| Placebo - UCB7665 (7 mg/kg) (SS) | 0/11 (0%) | 3/11 (27.3%) | 7/11 (63.6%) |
| Placebo - UCB7665 (4 mg/kg) (SS) | 0/11 (0%) | 1/11 (9.1%) | 9/11 (81.8%) |
| UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) (SS) | 0/10 (0%) | 1/10 (10%) | 8/10 (80%) |
| UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) (SS) | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Event | Placebo (SS) | UCB7665 (7 mg/kg) (SS) | Placebo - UCB7665 (7 mg/kg) (SS) | Placebo - UCB7665 (4 mg/kg) (SS) | UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) (SS) | UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) (SS) |
|---|---|---|---|---|---|---|
| Myasthenia gravis crisisNervous system disorders | 0/22 | 0/21 | 0/11 | 0/11 | 1/10 | 0/10 |
| Ulna fractureInjury, poisoning and procedural complications | 0/22 | 0/21 | 1/11 | 0/11 | 0/10 | 0/10 |
| HeadacheNervous system disorders | 0/22 | 0/21 | 1/11 | 0/11 | 0/10 | 0/10 |
| Myasthenia gravisNervous system disorders | 1/22 | 0/21 | 1/11 | 1/11 | 0/10 | 0/10 |
| PresyncopeNervous system disorders | 1/22 | 0/21 | 0/11 | 0/11 | 0/10 | 0/10 |
| Event | Placebo (SS) | UCB7665 (7 mg/kg) (SS) | Placebo - UCB7665 (7 mg/kg) (SS) | Placebo - UCB7665 (4 mg/kg) (SS) | UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) (SS) | UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) (SS) |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/22 | 12/21 | 3/11 | 2/11 | 4/10 | 4/10 |
| DiarrhoeaGastrointestinal disorders | 2/22 | 3/21 | 1/11 | 4/11 | 1/10 | 2/10 |
| NauseaGastrointestinal disorders | 0/22 | 2/21 | 0/11 | 0/11 | 1/10 | 2/10 |
| VomitingGastrointestinal disorders | 0/22 | 0/21 | 0/11 | 0/11 | 2/10 | 0/10 |
| DizzinessNervous system disorders | 3/22 | 0/21 | 0/11 | 0/11 | 2/10 | 1/10 |
| Myasthenic syndromeNervous system disorders | 0/22 | 0/21 | 0/11 | 0/11 | 2/10 | 1/10 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/22 | 0/21 | 2/11 | 0/11 | 0/10 | 1/10 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/22 | 0/21 | 0/11 | 2/11 | 1/10 | 0/10 |
| FatigueGeneral disorders | 3/22 | 0/21 | 1/11 | 1/11 | 0/10 | 0/10 |
| NasopharyngitisInfections and infestations | 3/22 | 0/21 | 0/11 | 0/11 | 1/10 | 0/10 |
Baseline Characteristics refer to the Randomized Set (RS) which consisted of all participants randomized into the study at the first randomization visit.
| Age, Categorical(Participants) | Placebo | UCB7665 (7 mg/kg) | Total Title |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 18 | 32 |
| >=65 years | 8 | 3 | 11 |
| Age, Continuous(years) | Placebo | UCB7665 (7 mg/kg) | Total Title |
|---|---|---|---|
| Mean | 53.3 ± 15.7 | 50.5 ± 14.7 | 51.9 ± 15.1 |
| Sex: Female, Male(Participants) | Placebo | UCB7665 (7 mg/kg) | Total Title |
|---|---|---|---|
| Female | 14 | 13 | 27 |
| Male | 8 | 8 | 16 |
| Race/Ethnicity, Customized(Participants) | Placebo | UCB7665 (7 mg/kg) | Total Title |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| Black | 1 | 1 | 2 |
| White | 19 | 20 | 39 |
| Other/mixed | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2017 to primary completion in May 2018, 12 months.
Results were first posted in Aug 2021, 3 years 2 months after primary completion. A results delay was requested in May 2019.
Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rozanolixizumab